Genmab today announced that the US FDA has accepted the Biologics License Application for Arzerra (ofatumumab) to treat patients whose chronic lymphocytic leukemia is resistant (refractory) to previous therapies and has granted ofatumumab priority review status.
The details can be read here.
No comments:
Post a Comment